Phaseline

Companies › Tasly Pharmaceuticals

Tasly Pharmaceuticals: clinical trials, targets and expected readouts

10 active drug programs in 10 registered trials: 6 Phase 3, 4 Phase 1; Cardiovascular, Oncology, Respiratory, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Jitongning tablets–Phase 3Ankylosing SpondylitisDec 2026
T89 capsule
Anti-anginal agent
–Phase 3Chronic Stable Angina PectorisDec 2026
Lianxiaxiaopi Granules
Traditional herbal medicine
–Phase 3Postprandial Distress SyndromeDec 2026
Qishen Yiqi Dripping Pills
Traditional Chinese medicine formulation
–Phase 3Heart FailureJun 2028
Antiwei Granules
Herbal formulation for wind-cold syndrome
–Phase 3Common Cold–
Xiang Ju Ru Pi Ning capsule
Traditional Chinese Medicine formulation for treatment of mammary gland hyperplasia
–Phase 3Hyperplasia of Mammary Glands–
B2278
Human umbilical cord mesenchymal stem cells (HucMSCs) with immune regulation, macrophage p
–Phase 1Coronary Artery Bypass Grafting (CABG)Dec 2026
TSL2109
CDK4/6-DYRK2 dual-target inhibitor
CDK4, CDK6, DYRK2Phase 1Metastatic Castration-Resistant Prostate Cancer PatientsDec 2026
B2065
allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection
–Phase 1Acute Ischemic StrokeDec 2027
P134 cells
CD44/CD133 dual-targeting CAR-T cells
CD44, CD133Phase 1Recurrent Glioblastoma IDH WildtypeFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06697886Antiwei GranulesPhase 3Common ColdRespiratoryJun 2025
NCT06685978Xiang Ju Ru Pi Ning capsulePhase 3Hyperplasia of Mammary GlandsOtherApr 2026
NCT06000956Jitongning tabletsPhase 3Ankylosing SpondylitisImmunologyDec 2026
NCT03789552T89 capsulePhase 3Chronic Stable Angina PectorisCardiovascularDec 2026
NCT07514065TSL2109Phase 1Metastatic Castration-Resistant Prostate Cancer PatientsOncologyDec 2026
NCT07265349B2278Phase 1Coronary Artery Bypass Grafting (CABG)CardiovascularDec 2026
NCT06696261Lianxiaxiaopi GranulesPhase 3Postprandial Distress SyndromeGastroenterologyDec 2026
NCT07371624B2065Phase 1Acute Ischemic StrokeNeurologyDec 2027
NCT07318818P134 cellsPhase 1Recurrent Glioblastoma IDH WildtypeOncologyFeb 2028
NCT07687186Qishen Yiqi Dripping PillsPhase 3Heart FailureCardiovascularJun 2028

Targets

CDK4 (1) CDK6 (1) DYRK2 (1) CD44 (1) CD133 (1)

Companies with the same targets

Pfizer Novartis Pharmacosmos Eli Lilly Jiangsu HengRui Medicine Shandong Suncadia Medicine Chia Tai Tianqing Pharmaceutical Group Jiangsu Simcere Pharmaceutical AstraZeneca Shanghai Hengrui Pharmaceutical

Companies built like this

Boryung Pharmaceutical Shandong Suncadia Medicine Sinotau Pharmaceutical Group InSilico Medicine Hong Kong THPharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.